Difference between revisions of "Sorafenib (Nexavar)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.univgraph.com/bayer/inserts/nexavar.pdf Sorafenib (Nexavar) package insert]</ref><ref>[http://hemonc.org/d...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http:// | + | Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf Sorafenib (Nexavar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/sorafenib.pdf Sorafenib (Nexavar) package insert (locally hosted backup)]</ref><ref>[http://www.nexavar.com Nexavar manufacturer's website]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/sorafenib. | + | *[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf#page=18 Sorafenib (Nexavar) package insert PDF pages 18-21]<ref name="insert"></ref> |
| + | *[http://chemocare.com/bio/sorafenib.asp Sorafenib (Nexavar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/sorafenib.asp Sorafenib (Nexavar) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:12, 24 February 2012
General information
Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Sorafenib (Nexavar) package insert PDF pages 18-21[1]
- Sorafenib (Nexavar) patient drug information (Chemocare)[4]
- Sorafenib (Nexavar) patient drug information (UpToDate)[5]